StockData

Nurix Therapeutics vs Ultragenyx Pharmaceutical

NRIX and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NRIX and RARE compare

Nurix Therapeutics and Ultragenyx Pharmaceutical are about the same size, with market caps of $1.6B and $1.6B.

Nurix Therapeutics grew revenue faster over the last twelve months (739% versus 17.5% for Ultragenyx Pharmaceutical).

Nurix Therapeutics keeps more of each dollar of sales as profit, with a net margin of 42.0% compared with −81.7% at Ultragenyx Pharmaceutical.

Nurix Therapeutics scores higher on the StockData Score (15 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNRIXRARE
Size and price
Market cap$1.6B$1.6B
Share price$14.73$15.90
Change, 1 year18.5%−51.7%
Change, 5 years−51.0%−79.2%
Beta (5Y)1.792.20
Employees3171,371
StockData Score
Total score15 (better)9
Valuation score4 (better)1
Growth score22
Performance score3 (better)1
Health score6 (better)5
Dividend score00
Valuation
P/E6.4×–
P/S2.3×2.2× (better)
P/B1.7×–
EV/EBITDA1.7×–
P/FCF4.4×–
FCF yield23.0% (better)−31.2%
Fair value$53.25–
Margin of safety72.3%–
Growth
Revenue growth (TTM)739% (better)17.5%
Revenue growth, 5Y average36.3% (better)19.9%
Profitability
Operating margin41.3% (better)−73.6%
Net margin42.0% (better)−81.7%
FCF margin52.7% (better)−68.2%
Return on equity44.0%–
Financial health
Debt / equity0.00–
Current ratio8.44 (better)1.73
Altman Z-score5.88 (better)−5.29
Piotroski F-score35 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield−1.1%–
Shareholder yield−1.1%0.00% (better)
Ownership
Held by institutions107%108%
Held by insiders0.75%4.0%
Insider net buying, 12 months−$5.2M−$3.8M (better)
Short interest, % of float17.5%25.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.